CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Intravenous drugWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug746 Sevoflurane Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D012128 Respiratory Distress Syndrome, Adult NIH 0.13

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial

The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering from COVID-19 ARDS.

NCT04355962 ARDS, Human Coronavirus Drug: Sevoflurane Drug: Intravenous drug
MeSH:Respiratory Distress Syndrome, Adult

Primary Outcomes

Description: The effect of sevoflurane application on mortality (rate of patients that does not survive 28 days) and persistent organ dysfunction (rate of patients surviving with a persistent organ failure at day 28) will be assessed. Organ failures are defined as pulmonary failure (necessity of ventilation); cardiovascular failure (need of vasopressors), retail failure (need of renal replacement therapy)

Measure: Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28

Time: 28 days

Secondary Outcomes

Description: The effect of sevoflurane application on the length of stay at ICU will be determined.

Measure: Length of stay ICU

Time: 28 days

Description: The impact of sevoflurane on the course of inflammatory markers will be evaluated (pro-calcitonin, PCT; c-reactive protein, CRP; interleukin 6, IL-6; monocyte chemoattractant protein 1, MCP-1)

Measure: Plasma Inflammatory markers

Time: 8 days

Description: The effect of sevoflurane application on the length of stay at hospital will be determined.

Measure: Length of stay at hospital

Time: 28 days

Description: Sex-related differences in complications will be assessed

Measure: Sex-related differences in complications

Time: 28 days

No related HPO nodes (Using clinical trials)